Anti-AURKA Polyclonal Antibody for WB and ELISA - O14965

Core Product Specifications and Parameters

Biological Background: AURKA Function and Localization

• AURKA is a mitotic serine/threonine kinase essential for cell cycle progression, centrosome maturation, and spindle assembly (PubMed:11039908, PubMed:12390251, PubMed:17125279, PubMed:14523000, PubMed:26246606). Related references: PMID:11039908, PMID:12390251, PMID:17125279, PMID:14523000, PMID:26246606
• It localizes to centrosomes, spindle poles, and basal bodies, and is required for proper chromosome alignment and cytokinesis (PubMed:14523000, PubMed:26246606). Related references: PMID:14523000, PMID:26246606
• AURKA phosphorylates numerous substrates including BORA, CDC25B, PLK1, and TPX2, thereby coordinating mitotic entry and progression (PubMed:11551964, PubMed:14702041, PubMed:15128871). Related references: PMID:11551964, PMID:14702041, PMID:15128871
• The kinase regulates microtubule dynamics by phosphorylating TACC3 and HDAC6, influencing spindle stability and cilia disassembly (PubMed:14702041, PubMed:17604723, PubMed:20643351). Related references: PMID:14702041, PMID:17604723, PMID:20643351
• It inhibits the tumor suppressor p53/TP53 via phosphorylation, promoting oncogenic transformation and is frequently overexpressed in cancer (PubMed:14702041). Related references: PMID:14702041
• AURKA is highly expressed in testis and weakly in skeletal muscle, thymus and spleen; also highly expressed in colon, ovarian, prostate, neuroblastoma, breast and cervical cancer cell lines.
• The activity of AURKA is regulated by ubiquitination and interaction with key mitotic regulators like TPX2 and protein phosphatase 1 (PubMed:11551964). Related references: PMID:11551964

Experimental Guidance and Technical Tips

• The immunogen corresponds to the N-terminal region (amino acids 1-130) of human AURKA; this region is unique and may minimize cross-reactivity with other aurora kinases, but validation in the relevant model system is recommended.
• For Western blot analysis, a band near 46 kDa is expected; consider using HeLa or another cancer cell line lysate as a positive control, and determine optimal antibody dilution empirically.
• In ELISA, coat plates with recombinant AURKA protein and titrate the antibody; pairing with a validated detection antibody may require individual optimization.
• To confirm specificity, siRNA-mediated knockdown of AURKA or pre-adsorption with immunogen can be employed; these controls are critical for published research.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your dedicated partner for sourcing high-quality IVD raw materials, offering one-stop access to validated antibodies, recombinant proteins, and ancillary reagents. This anti-AURKA polyclonal antibody is part of our expanding portfolio for oncology and cell cycle research, and we can support your project with bulk supply, custom development, and technical consulting. Contact us to streamline your assay development from concept to clinic.